WebApr 10, 2015 · Cell Signaling Technology's HER2/ErbB2 Antibody is a Rabbit Polyclonal antibody. This antibody has been shown to work in applications such as: Immunohistochemistry, Immunohistochemistry - fixed, and Western Blot. The HER2/ErbB2 Antibody was generated using ERBB2 as the antigen and it reacts with Human. … WebAug 14, 2024 · A BsAb named M802 that targets HER2 and CD3 was produced by introducing a salt bridge and knobs-into-holes (KIHs) packing into the structure. Flow cytometry was performed to determine its binding activity and cytotoxicity. ... 9271S), anti-pAkt (CST, 12694S), anti-Erk (CST, 9102S), anti-pErk (CST, 9106S), anti-cyckinD1 …
(4290) HER2/ErbB2 (D8F12) XP® Rabbit mAb - CiteAb
WebAug 5, 2014 · Abstract. Upregulation of HER2 is a hallmark of 20% to 30% of invasive breast cancers, rendering this receptor an attractive target for cancer therapy. Although HER2-targeting agents have provided … WebMay 20, 2024 · HER2/ErbB2 29D8 (clone 29D8, #2165, Cell Signaling Technology) at 1.28 μg/ml and a pressure boiling container (PT Module, Lab Vision, Thermo Scientific, Waltham, MA) were used in the Rimm Lab ... portable storage pods houston
SUPPLEMENTAL INFORMATION METHODS - Gut
WebMar 21, 2024 · Tocris Summary for ERBB2 Gene. The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family. Four members of the ErbB family have been identified; EGFR (ErbB1, HER1), ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4). EGFR signaling drives many cellular responses. WebFeb 21, 2024 · CST), HER2/ErbB2 XP (D8F12, rabbit IgG, CST), EGF receptor XP (D38B1, rabbit IgG, CST), phospho-AKT XP (Ser473; D9E, rabbit, IgG, CST), AKT (rabbit polyclonal, CST), phospho- GSK3α/β (Ser21/9; D17D2, rabbit IgG, CST), GSK-3β (27C10, rabbit IgG, CST), phospho-ERK 1/2 ... CST). β-actin (8H10D10, mouse, CST) was used as loading … WebHER2 is a protein that helps breast cancer cells grow quickly. Breast cancer cells with higher than normal levels of HER2 are called HER2-positive . These cancers tend to grow and spread faster than breast cancers that are HER2-negative, but are much more likely to respond to treatment with drugs that target the HER2 protein . irs created when